Top Market Shifts Transforming the Drug Eluting Stent Market Landscape: Key Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Drug Eluting Stent Market Through 2025?
The market size for drug eluting stents has seen significant growth over recent years, projected to grow from $7.63 billion in 2024 to $8.26 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 8.3%. The expansion in the historical period can be ascribed to factors such as the demand for more advanced treatment options, compelling clinical data, approval from regulatory bodies, health economics, and established guidelines and recommendations.

What's the Projected Size of the Global Drug Eluting Stent Market by 2029?
The market size for the drug eluting stent is anticipated to experience considerable expansion in the upcoming years, projected to reach $11.07 billion in 2029 with a compound annual growth rate (CAGR) of 7.6%. Factors driving this growth during the forecast period include an increase in older populations and chronic illnesses, broadening of indications, the evolution of healthcare reimbursement policies, expansion of the global market, and focus on patient-oriented care. Key trends for the forecast period encompass individualized medicine, less invasive procedures, the rise of emerging healthcare technologies, and the development of next-generation drug formulations.

View the full report here:
https://www.thebusinessresearchcompany.com/report/drug-eluting-stent-global-market-report

Top Growth Drivers in the Drug Eluting Stent Industry: What's Accelerating the Market?
The mounting prevalence of coronary heart disease is projected to stimulate the expansion of the drug-eluting stent industry. This consistent growth is attributed to coronary heart disease (CHD), a condition in which plaque accumulation narrows or obstructs the coronary arteries and can result in serious complications like heart attacks or chest pain. Contributing factors such as sedentary lifestyle, unhealthy food habits, aging demographics, and increased awareness are the chief reasons for the rising incidence of coronary heart disease. The functional usefulness of drug-eluting stents (DES) in coronary heart disease is their ability to effectively unblock or widen narrowed coronary arteries, and they also dispense drugs that aid in preventing the arteries from re-narrowing (restenosis). For instance, the Centers for Disease Control and Prevention, a US governmental institution, reported in May 2024 that the incidence of coronary heart disease in adults aged 18 and above was 4.6% in 2020, which escalated to 4.9% in 2022. Hence, the growing incidence of coronary heart disease is anticipated to drive the advancement of the drug-eluting stent industry.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15557&type=smp

Which Emerging Trends Are Transforming the Drug Eluting Stent Market in 2025?
In the drug-eluting stent market, businesses are honing in on the creation of inventive delivery mechanisms, an example of which is the dual-layer balloon, with the aim of enhancing patient results and pushing forward the specialty of interventional cardiology. A drug-eluting stent system that incorporates a dual-layer balloon boosts accuracy in both drug delivery and stent placement, offering superior control and even applying medication to the arterial wall. For example, in August 2022, Medtronic Plc, a medical supplies company based in Ireland, released Onyx Frontier, the newest version of its drug-eluting coronary stent systems devised to augment delivery systems - a development based on the acute performance and clinical data from the earlier generation of Resolute Onyx DES. The Onyx Frontier DES makes use of the same top-tier stent platform as Resolute Onyx, capable of treating patients with diameters ranging from 2.0mm to 5.0mm thanks to its extensive size matrix. The Onyx Frontier DES introduces significant design enhancements, inclusive of a cutting-edge dual-layer balloon, a smaller crossing profile, and superior catheter flexibility. These enhancements have resulted in a deliverability improvement of 16% compared to the previous generation of the Resolute Onyx DES, without compromising radial strength.

What Are the Main Segments in the Drug Eluting Stent Market?
The drug eluting stent market covered in this report is segmented -

1) By Product: Polymer-Based, Polymer-Free
2) By Drug: Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, Other Drugs
3) By Scaffold: Cobalt-Chromium, Platinum-Chromium, Nitinol, Biodegradable, Other Scaffolds
4) By Application: Coronary Diseases, Peripheral Vascular Diseases
5) By End-User: Hospitals, Specialty Clinic

Subsegments:
1) By Polymer-Based: Durable Polymer Drug-Eluting Stents, Biodegradable Polymer Drug-Eluting Stents
2) By Polymer-Free: Bare-Metal Stents With Drug Coating, Other Polymer-Free Drug-Eluting Stents

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15557&type=smp

Which Top Companies are Driving Growth in the Drug Eluting Stent Market?
Major companies operating in the drug eluting stent market are Johnson & Johnson Services Inc., Abbott, Medtronic plc, Boston Scientific Corporation, Terumo Corporation, InspireMD Inc., B. Braun Melsungen AG, Cook Group Incorporated, Lepu Medical Technology (Beijing) Co. Ltd., Biotronik, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, Biosensors International Group Ltd., OrbusNeich Medical Company Limited, Alvimedica Medical Technologies, Hexacath, Elixir Medical Corporation, Translumina GmbH, Cardionovum GmbH, QualiMed Innovative Medizinprodukte GmbH, InSitu Technologies Inc., Acrostak AG, SINOMED Innovation Inc., Svelte Medical Systems Inc.

Which Regions Will Dominate the Drug Eluting Stent Market Through 2029?
North America was the largest region in the drug-eluting stent market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15557

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.